Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition
Excerpt from the Press Release:
WALTHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (NASDAQ: MORF) today announced the presentation of new preclinical data in the MORF-057 IBD development program that are consistent with previous findings and add new support to mechanistic understanding of the molecule’s activity in a nonhuman primate (NHP) model of ulcerative colitis. The poster presentation was made at Digestive Disease Week (DDW) 2023.
“The data presented at DDW continue to refine and reinforce our understanding of the pharmacokinetic-pharmacodynamic relationship of α4β7 inhibition with respect to cellular biomarkers and MORF-057’s translation to treatment of patients. Further, these results link Morphic’s small molecule α4β7 inhibitors with the pharmacology associated with approved anti-integrin IBD treatments,” commented Bruce Rogers, PhD, President of Morphic.
The study presented at DDW examines longitudinal changes in circulating biomarkers in nonhuman primates (NHP) infused with stepwise increasing doses of MT-105, a small-molecule, selective α4β7 integrin inhibitor tool compound with similar chemical properties to MORF-057.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?